Empagliflozin is an oral antidiabetic medicine belonging to the SGLT2 inhibitor class, primarily used in the management of type 2 diabetes mellitus. It works by blocking sodium‑glucose co‑transporter‑2 in the kidneys, which reduces glucose reabsorption and promotes its excretion through urine, thereby lowering blood sugar levels. Beyond glycemic control, empagliflozin has shown significant benefits in reducing the risk of cardiovascular events such as heart attack and stroke in diabetic patients with existing heart disease. It is also prescribed to improve outcomes in heart failure with reduced ejection fraction, regardless of diabetes status, and to protect kidney function in patients with chronic kidney disease.